阿替利珠单抗联合贝伐单抗用于晚期肝细胞癌临床实践的初步经验
Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.
作者信息
Kuzuya Teiji, Kawabe Naoto, Hashimoto Senju, Miyahara Ryoji, Nakano Takuji, Nakaoka Kazunori, Tanaka Hiroyuki, Miyachi Yohei, Mii Arisa, Tanahashi Yoshinao, Kato Yutaro, Sugioka Atsushi, Hirooka Yoshiki
机构信息
Department of Gastroenterology and Hepatology, Fujita Health University, Aichi, Japan.
Department of Surgery, Fujita Health University, Aichi, Japan.
出版信息
Cancer Diagn Progn. 2021 May 3;1(2):83-88. doi: 10.21873/cdp.10012. eCollection 2021 May-Jun.
Abstract
BACKGROUND/AIM: The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice.
PATIENTS AND METHODS
Of 34 patients treated with atezolizumab plus bevacizumab, a total of 23, including 16 with lenvatinib failure, were enrolled in this retrospective study. The adverse events, changes in liver function and antitumor responses at 6 weeks after starting therapy were evaluated.
RESULTS
The incidence of grade 3 adverse events was low, at 13.0%. Albumin-bilirubin scores did not worsen at 3 and 6 weeks compared to baseline. The objective response rate and disease control rate at 6 weeks were 17.4% and 78.3% according to Response Evaluation Criteria in Solid Tumors (RECIST), and 30.4% and 78.3% according to modified RECIST, respectively.
CONCLUSION
Our results suggest that atezolizumab plus bevacizumab might have potential therapeutic safety and efficacy in patients with advanced HCC, including those with disease refractory to lenvatinib. Further studies are needed to confirm the outcomes of atezolizumab plus bevacizumab after lenvatinib failure.
摘要
背景/目的：本研究旨在探讨在临床实践中，阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌（HCC）患者的疗效，包括对乐伐替尼耐药的患者。
患者与方法
在34例接受阿替利珠单抗联合贝伐珠单抗治疗的患者中，共有23例患者纳入本回顾性研究，其中16例为乐伐替尼治疗失败的患者。评估了治疗开始后6周时的不良事件、肝功能变化和抗肿瘤反应。
结果
3级不良事件的发生率较低，为13.0%。与基线相比，3周和6周时的白蛋白-胆红素评分没有恶化。根据实体瘤疗效评价标准（RECIST），6周时的客观缓解率和疾病控制率分别为17.4%和78.3%；根据改良RECIST标准，分别为30.4%和78.3%。
结论
我们的结果表明，阿替利珠单抗联合贝伐珠单抗可能对晚期HCC患者具有潜在的治疗安全性和疗效，包括对乐伐替尼耐药的患者。需要进一步研究以证实乐伐替尼治疗失败后阿替利珠单抗联合贝伐珠单抗的疗效。
相似文献
1
Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.阿替利珠单抗联合贝伐单抗用于晚期肝细胞癌临床实践的初步经验
Cancer Diagn Progn. 2021 May 3;1(2):83-88. doi: 10.21873/cdp.10012. eCollection 2021 May-Jun.
2
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗在不可切除肝细胞癌序贯治疗中的作用。
Anticancer Res. 2022 Mar;42(3):1403-1412. doi: 10.21873/anticanres.15610.
3
Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的初步经验：一项真实世界回顾性研究。
Anticancer Res. 2022 Nov;42(11):5465-5473. doi: 10.21873/anticanres.16051.
4
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.仑伐替尼与阿替利珠单抗联合贝伐珠单抗作为不可切除肝细胞癌一线治疗的疗效和安全性相当。
Cancer Med. 2023 Mar;12(6):7077-7089. doi: 10.1002/cam4.5506. Epub 2022 Dec 5.
5
Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.一线阿替利珠单抗联合贝伐单抗治疗进展后，乐伐替尼在晚期肝细胞癌患者中的疗效和安全性
Anticancer Res. 2023 Mar;43(3):1377-1384. doi: 10.21873/anticanres.16286.
6
Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.仑伐替尼再挑战治疗在阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌后的肝癌。
Anticancer Res. 2022 Nov;42(11):5479-5486. doi: 10.21873/anticanres.16053.
7
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.阿替利珠单抗联合贝伐珠单抗或仑伐替尼治疗肝细胞癌患者的临床结局：一项多中心真实世界研究。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602. doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
8
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.阿替利珠单抗联合贝伐珠单抗对比乐伐替尼用于 Child Pugh B 不可切除肝细胞癌患者的生存结局。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7565-7577. doi: 10.1007/s00432-023-04678-2. Epub 2023 Mar 28.
9
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.阿替利珠单抗联合贝伐单抗与乐伐替尼治疗不可切除肝细胞癌：一项全球大型真实世界研究。
Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25.
10
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.贝伐珠单抗联合阿替利珠单抗治疗不可切除肝细胞癌的真实世界实践：日本患者的早期经验。
Invest New Drugs. 2022 Apr;40(2):392-402. doi: 10.1007/s10637-021-01185-4. Epub 2021 Sep 29.
引用本文的文献
1
Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies.在真实世界研究中报告的与阿替利珠单抗-贝伐单抗治疗肝细胞癌相关的不良事件的异质性。
JHEP Rep. 2024 Aug 22;6(11):101190. doi: 10.1016/j.jhepr.2024.101190. eCollection 2024 Nov.
2
Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.阿替利珠单抗联合贝伐珠单抗作为不可切除肝细胞癌二线治疗的疗效。
PLoS One. 2024 Apr 30;19(4):e0298770. doi: 10.1371/journal.pone.0298770. eCollection 2024.
3
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌合并门静脉高压患者的疗效和安全性。
Cancer Med. 2024 Mar;13(5):e7025. doi: 10.1002/cam4.7025.
4
Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.分子靶向药物抑制成纤维细胞生长因子可减轻肝癌的免疫抑制性组织微环境。
Hepatol Int. 2024 Apr;18(2):610-622. doi: 10.1007/s12072-023-10603-z. Epub 2023 Oct 21.
5
Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma-Importance of Good Liver Function and Good Performance Status.卡博替尼用于曾接受阿替利珠单抗/贝伐单抗治疗的晚期肝细胞癌患者的临床疗效——良好肝功能和良好体能状态的重要性
Cancers (Basel). 2023 May 28;15(11):2952. doi: 10.3390/cancers15112952.
6
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.使用实体瘤疗效评价标准和甲胎蛋白联合评估阿替利珠单抗联合贝伐单抗治疗晚期肝细胞癌患者的疗效
Cancers (Basel). 2023 Apr 14;15(8):2304. doi: 10.3390/cancers15082304.
7
Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma.开始使用阿替利珠单抗联合贝伐单抗治疗后三个月内ALBI评分和异常凝血酶原-II的变化影响不可切除肝细胞癌患者的总生存期。
Cancers (Basel). 2022 Dec 10;14(24):6089. doi: 10.3390/cancers14246089.
8
Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma.预处理改良白蛋白-胆红素分级是与不可切除肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗治疗的应答和继续治疗相关的重要预测因素。
Curr Oncol. 2022 Jul 8;29(7):4799-4810. doi: 10.3390/curroncol29070381.
9
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.阿替利珠单抗和贝伐单抗用于肝功能受损且既往接受过全身治疗的晚期肝细胞癌患者：一项真实世界经验
Ther Adv Med Oncol. 2022 Feb 26;14:17588359221080298. doi: 10.1177/17588359221080298. eCollection 2022.
10
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌患者在真实世界中的早期肿瘤反应及安全性
Cancers (Basel). 2021 Aug 5;13(16):3958. doi: 10.3390/cancers13163958.
本文引用的文献
1
Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.对于不可切除肝细胞癌患者，在乐伐替尼治疗失败后，索拉非尼作为二线治疗选择。
JGH Open. 2020 Aug 15;4(6):1135-1139. doi: 10.1002/jgh3.12408. eCollection 2020 Dec.
2
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.乐伐替尼治疗门静脉主干有瘤栓或肿瘤占肝体积超过50%的高度进展性肝细胞癌的疗效分析：一项多中心分析。
Hepatol Res. 2021 Feb;51(2):201-215. doi: 10.1111/hepr.13592. Epub 2021 Jan 5.
3
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.晚期肝细胞癌的系统治疗：ASCO 指南。
J Clin Oncol. 2020 Dec 20;38(36):4317-4345. doi: 10.1200/JCO.20.02672. Epub 2020 Nov 16.
4
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.肝细胞癌的试验设计与终点：美国肝病研究学会共识会议
Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
6
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.肝细胞癌全身治疗的新时代：阿替利珠单抗联合贝伐珠单抗联合疗法。
Liver Cancer. 2020 Apr;9(2):119-137. doi: 10.1159/000505189. Epub 2020 Mar 5.
7
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.晚期肝细胞癌中PD-1/PD-L1抗体与VEGF抑制剂联合免疫治疗的科学依据
Cancers (Basel). 2020 Apr 27;12(5):1089. doi: 10.3390/cancers12051089.
8
Sorafenib . Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.索拉非尼、仑伐替尼作为伴门静脉癌栓的晚期肝细胞癌一线治疗药物。
Anticancer Res. 2020 Apr;40(4):2283-2290. doi: 10.21873/anticanres.14193.
9
Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.仑伐替尼治疗失败后使用雷莫芦单抗治疗晚期肝细胞癌的初步经验。
Anticancer Res. 2020 Apr;40(4):2089-2093. doi: 10.21873/anticanres.14167.
10
Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma.对于晚期肝细胞癌患者，在开始使用乐伐替尼治疗2周后出现了良好的放射学抗肿瘤反应。
Hepatol Res. 2020 Mar;50(3):374-381. doi: 10.1111/hepr.13452. Epub 2019 Dec 22.
Zotero 插件